Clinical Trial Update: Firmagon (Degarelix) Intermittent Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial update for Degarelix (Firmagon) intermittent therapy in recurrent prostate cancer; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Firmagon (Degarelix)

Snippet

Sponsor: Canadian Urology Research Consortium | Conditions: Prostate Cancer Recurrent | Phase 4 | Status: TERMINATED